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Abstract
Orf virus (OV), the prototypic parapoxvirus, is resistant to the effects of interferon (IFN) and this function of OV has been mapped to
the OV20.0L gene. The protein product of this gene shares 31% amino acid identity to the E3L-encoded protein of vaccinia virus (VV) that
is required for the broad host range and IFN-resistant phenotype of VV in cells in culture and for virulence of the virus in vivo. In this study
we investigated whether the distantly related OV E3L homologue could complement the deletion of E3L in VV. The recombinant VV
(VV/ORF-E3L) expressing the OV E3L homologue in place of VV E3L was indistinguishable from wt VV in its cell-culture phenotype.
But VV/ORF-E3L was over a 1000-fold less pathogenic than wt VV (LD50  5  106 PFU, compared to LD50 of wtVV  4  103 PFU)
following intranasal infection of mice. While wt VV spread to the lungs and brain and replicated to high titers in the brain of infected mice,
VV/ORF-E3L could not be detected in the lungs or brain following intranasal infection. VV/ORF-E3L was at least 100,000-fold less
pathogenic than wt VV on intracranial injection. Domain swap experiments demonstrate that the difference in pathogenesis maps to the
C-terminal domain of these proteins. This domain has been shown to be required for the dsRNA binding function of the VV E3L.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The interferon (IFN) system is one of the primary mam-
malian defenses against virus infection. The primary role
played by IFN in up-regulating immune functions and es-
tablishing an antiviral state in host cells can be appreciated
by the fact that poxviruses encode at least five proteins that
prevent induction, receptor binding, or action of IFNs
(Smith et al., 1998).
Orf virus (OV) is an animal pathogen belonging to the
Parapoxvirus genus that causes contagious ecthyma marked
by acute cutaneous lesions in sheep and goat (Robinson and
Balassu, 1981). The virus infects through damaged skin,
replicates in regenerating epidermal cells, and induces pus-
tular lesions that turn into scabs. No evidence of systemic
spread of the virus is seen in infected animals (Haig and
Mercer, 1998). OV is resistant to the effects of IFN in
cell-culture studies (McInnes et al., 1998). The protein re-
sponsible for the IFN-resistant phenotype of the virus was
identified to be encoded by the OV20.0L gene. The product
of this gene shares 31% amino acid identity with the IFN
resistance protein, E3L, encoded by vaccinia virus (VV)
(Haig et al., 1998).
The VV E3L is thought to inhibit the IFN system by
sequestering dsRNA that triggers antiviral pathways medi-
ated through the double-stranded RNA-dependent protein
kinase (PKR) and a family of 25-oligoadenylate syntheta-
ses (Jacobs and Langland, 1996). The VV E3L gene en-
codes two gene products having relative molecular weights
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of 25 and 20 kDa. The synthesis of the smaller product is
likely the result of “leaky scanning” past the first translation
initiation codon. Activated PKR inactivates the translation
initiation factor eIF2 by phosphorylation of the -subunit,
thereby inhibiting initiation of protein synthesis (Sen and
Lengyel, 1992). The 25-oligoadenylate synthetases cata-
lyze the synthesis of a family of oligonucleotides that acti-
vate a latent endonuclease RNase L which in turn degrades
cellular and viral RNAs (Rivas et al., 1998). Presumably by
inhibiting activation of PKR and 25-oligoadenylate syn-
thetase, the VV E3L gene products inhibit the block of
translation in infected cells, thereby enabling virus replica-
tion (Chang et al., 1995). The E3L-encoded proteins enable
VV to be resistant to the effects of IFN and overcome host
range restrictions in cells-in-culture (Chang et al., 1995;
Shors et al., 1997). The products of the E3L gene also
protect vesicular stomatitis virus from the effects of IFN
(Shors et al., 1998).
The VV E3L-encoded proteins contain a conserved C-
terminal consensus dsRNA-binding domain (Chang and Ja-
cobs, 1993) that is also necessary for oligomerization (Ho
and Shuman, 1996b). This domain is both necessary and
sufficient for IFN-resistance and the wide host range of VV
in cells in culture (Chang et al., 1995; Beattie et al., 1996;
Shors et al., 1997). The N-terminus of the E3L-encoded
proteins contains a consensus Z-DNA-binding domain
(Schade et al., 1999; Schwartz et al., 1999) that is dispens-
able in cells in culture: virus containing a large N-terminal
deletion is IFN-resistant and replicates in a wide variety of
cells in culture (Chang et al., 1995; Beattie et al., 1996;
Shors et al., 1997). The N-terminus also appears to be
necessary for nuclear localization of E3L-encoded proteins
(Yuwen et al., 1993; Chang et al., 1995) and may directly
interact with PKR (Romano et al., 1998). The N-terminal
Z-DNA-binding domain and the C-terminal dsRNA-binding
domain are linked by an acidic, trypsin-sensitive sequence
(Ho and Shuman, 1996b). While the N-terminal domain is
dispensable for replication in cells in culture, both domains
are required for pathogenesis in a mouse model system
(Brandt and Jacobs, 2001).
Although the relationship of the orthopox viruses with
the parapox genus is fairly distant, both the N- and the
C-terminal domains of VV E3L are fairly conserved in the
OV E3L homologue encoded by OV20.0L gene. We there-
fore investigated the ability of the OV E3L homologue to
replace E3L of VV in vitro and in vivo. Our studies dem-
onstrate that the OV E3L was able to rescue the host range
restriction and IFN-sensitive phenotype of VV deleted of
E3L gene (VVE3L) in cells-in-culture. However, VV ex-
pressing the OV E3L was over 1000-fold less pathogenic
than wt VV in the animal model. By swapping the domains
of OV E3L homologue and VV E3L, we were able to map
the reduced virulence of the recombinant virus expressing
OV E3L to the C-terminal dsRNA-binding domain of the
protein.
Results
Sequence comparisons
Although OV is a member of parapox genus that is only
distantly related to orthopox viruses, OV E3L showed 44%
nucleotide identity and 31% amino acid identity (57% sim-
ilarity) with VV E3L. The sequence alignment of OV E3L
homologue (OV20.0L gene of NZ2 strain of OV) with VV
E3L (WR strain) revealed that both the N-and the C-termi-
nal domains of VV E3L are conserved in OV E3L (Fig. 1).
A divergent acidic domain, which is trypsin sensitive, links
the dual domains of these proteins (Ho and Shuman,
1996b).
Fig. 1. Alignment of the amino acid sequence of the E3L-encoded proteins of VV and OV. The top alignment represents the pairwise comparison of the
conserved N-terminal domain; the middle alignment represents the linker region and the lower alignment represents the C-terminal domain of both the
proteins. A consensus Z-DNA-binding domain is shown, with asterisks defining residues found in the hydrophobic core of the protein and lettered residues
indicating residues that contact Z-DNA in the crystal structure of ADAR1 Z bound to Z-DNA. A consensus dsRNA-binding motif is shown below the lower
alignment, with residues in OV E3L that differ from the consensus and from VV E3L underlined. Pluses indicate conserved residues.
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Protein expression
Expression and stability of the E3L proteins of VV and
OV were determined by pulse-chase analysis. 35S-labeled
infected cell lysates, prepared 4 h postinfection, were sep-
arated by binding to dsRNA agarose and analyzed by SDS–
PAGE electrophoresis to determine protein expression. VV
E3L expresses two proteins (25 and 20 kDa in size), the
second one likely being produced by leaky scanning from
the second initiation codon at codon 38 (Yewen et al.,
1993). OV E3L also produced two proteins capable of
binding to dsRNA having relative molecular weights of
approximately 25 and 12 kDa (Fig. 2). Similar to VV E3L,
it was likely that the smaller protein, p12, was produced by
leaky scanning to the next downstream initiator codon of the
OV E3L gene at codon 80. The protein product produced
from this second initiator codon would have an expected
molecular weight of approximately 12 kDa. Densitometric
analysis of the ORF E3L proteins suggests that the p12
protein was produced in a 2–3 molar excess as compared to
the full-length product, p25 (data not shown). Both VV E3L
and OV E3L were found to be stable on pulse-chase anal-
ysis and approximately 50% of both these proteins were
found in infected cells following a 3-h chase period (data
not shown).
IFN sensitivity and host range
Both VV and OV are resistant to the effects of IFN and
this has been mapped to the E3L genes of these viruses
(Haig et al., 1998; Beattie et al., 1995). The E3L gene of VV
is also required for this virus to plaque in HeLa cells. As
shown in Fig. 3, VVE3L was sensitive to IFN and unable
to plaque in RK-13 cells pretreated with 100 and 1000
IU/ml of rabbit IFN. This virus was also unable to plaque
in HeLa cells even in the absence of IFN treatment (Beattie
et al., 1996). VV/ORF-E3L was IFN resistant (Fig. 3) with
a broad host range similar to that of wtVV (data not shown).
Thus OV E3L was able to restore the IFN-resistant pheno-
type and broad host range of VVE3L in cells-in-culture.
Intranasal infection of mice
wtVV is highly pathogenic in C57BL/6 mice. The dose
that kills 50% of infected mice (LD50) of this virus was
determined to be 4  103 PFU (Reed and Muench, 1938)
when infected by the intranasal route (Fig. 4A). Infected
mice were anorexic with ruffled fur and showed signs of
paralysis in the latter stage of infection. VVE3L is non-
pathogenic in mice even at the highest dose (106 PFU)
administered (Brandt and Jacobs, 2001). Since OV E3L is
able to complement the deletion of VV E3L in cells-in-
culture, we analyzed whether similar results would be ob-
tained in the animal model. Surprisingly, VV/ORF-E3L was
nonpathogenic in mice even at the highest dose (5  106
PFU) administered by the intranasal route (Fig. 4). No
clinical signs were observed in mice infected with VVE3L
or VV/ORF-E3L. A revertant prepared from VV/ORF-E3L
(VV/ORF-E3L rev) was similar in pathogenicity to wtVV
(Fig. 4), thereby excluding the possibility of second site
mutations in VV/ORF-E3L as a possible cause of debilita-
tion of this virus.
The body weights of the infected mice were recorded on
days 0, 2, 4, 6 and 8 postinfection by intranasal route. The
percentage weight change of mice given the similar doses of
each virus was compared. Mock-infected mice recorded
normal weight gain. A similar weight gain pattern was
observed in mice infected with VVE3L and VV/ORF-E3L
(Fig. 4B). Mice infected with wtVV and VV/ORF-E3L rev
lost over 30% of their body weight in 8 days.
Fig. 3. Plaque reduction assay to determine IFN sensitivity of VV/OV-E3L.
RK-13 cells were pretreated with doses of rabbit IFN ranging from 0 to
1000 U/ml for 16 h and then infected with 100 PFU of each virus. The cells
were stained with crystal violet 36–48 h postinfection and plaques were
counted. The data are shown as percentage of the plaques seen at 0 U/ml
of IFN.
Fig. 2. Protein expression in cells infected with VV/OV-E3L. RK-13 cells
were infected at an m.o.i. of 5 with VVE3L or VV/OV-E3L. Control cells
were mock-infected with Tris–HCl pH 8.0. The cells were labeled with
[35S]methionine at 3–4 h postinfection and harvested. The E3L proteins
were bound to dsRNA-agarose analyzed by SDS–PAGE electrophoresis on
a 15% gel and subjected to autoradiography.
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Tissue distribution
To begin characterizing the lack of pathogenicity of
VV/ORF-E3L, the distribution of the virus in the various
tissues after intranasal infection was determined. wtVV
replicates to high titers in the nose of mice following intra-
nasal infection. By 4 days postinfection the virus is detected
in the lungs and brain of infected mice and animals die of
encephalitis 6–12 days postinfection (Brandt and Jacobs,
2001). Therefore we infected mice with 106 PFU of wtVV,
VVE3L, and VV/ORF-E3L. Mock-infected mice were
used as controls. Low levels of VVE3L were detected in
the nose of infected mice but no virus was detectable in the
lungs or brain (Fig. 5). VV/ORF-E3L replicated to levels
comparable to wtVV in the nose of infected mice. However
the virus did not spread to the lungs and brain of infected
mice (Fig. 5). Thus the reduced pathogenicity of VV/ORF-
E3L in infected mice appeared to be due to reduced spread
of the virus from the site of infection.
Survival of mice following intracranial infection
Since VV is thought to cause mortality by replication in
the brain, we investigated the ability of VV/ORF-E3L to
cause lethality in mice if the virus was administered directly
into the brain. wtVV had a LD50 of approximately 100 PFU,
while VVE3L did not cause pathogenicity even at the
highest dose (106 PFU) administered. Interestingly, only
20% of the infected mice died even on administration of 107
PFU of VV/ORF-E3L into the brain (Fig. 6). Thus VV
expressing OV E3L was over 100,000-fold less pathogenic
than wtVV following intracranial injection of virus. Viral
loads in the brains of these mice suggest that wtVV repli-
cates well in the brain of infected mice, whereas VVE3L
and VV/OV-E3L replicate poorly, if at all, in the brain of
infected mice (data not shown).
Chimeric E3L constructs
Both the N- and the C-terminal domains of OV E3L are
fairly well conserved in VV E3L (Haig et al., 1998). Studies
done by Brandt and Jacobs (2001) demonstrated that both
the N- and the C-terminal domains of VV E3L were re-
quired for virulence. To determine the reason for the re-
duced virulence of VV/OV-E3L, the domains of VV E3L
Fig. 4. Pathogenicity to mice following intranasal infection with wtVV,
VVE3L, VV/OV-E3L, and VV/OV-E3L revertant (VV/OV-E3L rev).
(A) Groups of six C57BL/6 mice 4–5 weeks of age were infected with the
indicated virus doses of wtVV, VV/OV-E3L, VVE3L, or VV/OV-E3L
revertant and observed for 2 weeks. All deaths were recorded and the
percentage survival of mice infected with each virus was calculated. (B)
Groups of six C57BL/6 mice infected with 104 PFU of each virus (wtVV,
VVE3L, VV/OV-E3L, or VV/OV-E3Lrev). Mock-infected animals were
used as controls. The mice were weighed on days 0, 2, 4, 6, and 8
postinfection. The percentage weight change was calculated.
Fig. 5. Tissue distribution of wtVV, VVE3L, and VV/OV-E3L. Two
C57BL/6 mice, 4 weeks of age, were infected with 106 PFU of each virus
by the intranasal route. Nose, brain, and lungs were harvested 5 days
postinfection and processed. Viral load in each tissue was determined by
titration on RK-13 cells. The viral load in each organ was expressed as
PFU/gram of tissue. Error bars represent standard deviation.
Fig. 6. Survival of mice following intracranial injection with wtVV,
VVE3L, and VV/OV-E3L. Groups of 5–6 C57BL/6 mice, 4–5 weeks of
age, were infected with virus doses ranging from 103 to 107 PFU by the
intracranial route and the animals were observed for 2 weeks. All deaths
were recorded and the survival percentage of mice infected with each virus
was determined.
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and OV E3L were interchanged to generate chimeric E3L
genes VV-N/OV-C and OV-N/VV-C, as described under
Materials and methods. The chimeric E3Ls were recom-
bined into the E3L locus of VVE3L to generate recombi-
nant VV. These viruses were characterized in cells-in-cul-
ture by performing plaque reduction assays and host range
studies. Viruses expressing the chimeric proteins were IFN
resistant and had a broad host range indistinguishable from
wtVV and VV/OV-E3L in cells-in-culture (data not shown).
Survival of mice following intranasal infection with the
chimeric E3L viruses
Various doses of VV expressing the chimeric E3L pro-
teins were used to infect C57BL/6 mice and the viral patho-
genicity was compared to wtVV as well as VV/OV-E3L as
shown in Fig. 7. OV-N/VV-C was as pathogenic as wtVV in
mice. The chimera VV-N/OV-C was as debilitated as VV/
OV-E3L. This suggests that the conserved residues in the
N-terminal domain of OV E3L seem to be sufficient to
replace the function of N-terminus of VV E3L, but the
C-terminal domain of OV E3L was unable to replace the
function of the corresponding domain of VV E3L.
Discussion
The E3L gene of VV is highly conserved among most
members of orthopox genus and many orthopoxviruses en-
code E3L genes with more than 90% sequence identity with
VV E3L. Of the poxviruses sequenced in their entirety, only
fowlpox and molluscum contagiosum viruses lack an E3L-
like gene. Even OV, a member of the distantly related
parapox genus, encodes an E3L homologue which shares
31% amino acid identity to VV E3L. Most of the amino acid
residues that are conserved in the dual domains of the E3Ls
of orthopoxviruses are also conserved in OV E3L.
The role of E3L genes of OV and VV were examined by
constructing a recombinant VV (VV/OV-E3L) by inserting
OV E3L homologue (OV20.0L gene, NZ2 strain), into the
E3L locus of VV (WR strain) by in vivo recombination. The
phenotype of VV/OV-E3L in cells-in-culture was compared
with that of wtVV and VVE3L to determine whether the
OV E3L homologue could replace the function of E3L in
VV. The E3L gene of VV is required for the IFN-resistant
phenotype and broad host range of VV in cells-in-culture
and this phenotype of VV is associated with the ability of
E3L-encoded protein to bind to dsRNA (Shors et al., 1997).
OV E3L was able to rescue the IFN-sensitive, restricted host
range phenotype of VVE3L. This is in agreement with the
observation that expression of heterologous dsRNA-binding
proteins such as rotavirus NSP3 gene product (Langland et
al., 1994), and reovirus 3 protein (Beattie et al., 1995),
could complement the deletion of VV E3L in cells-in-
culture.
Although VV/OV-E3L was similar to wtVV in its cell-
culture phenotype, this similarity did not extend to the
results obtained in animal studies. wtVV was pathogenic in
4- to 5-week-old C57BL/6 mice infected by intranasal route
with a LD50 of 4  103 PFU. VV/OV-E3L had a LD50
greater than 5  106 PFU, making this virus more than a
1000-fold less pathogenic than wtVV. The decreased patho-
genicity of VV/OV-E3L was reflected not only in the ab-
sence of lethality observed on intranasal infection with this
virus but also in the altered weight change pattern in in-
fected mice. Weight loss is a reliable indicator of the rela-
tive pathogenesis of poxviruses (Bloom et al., 1991). Our
studies revealed that mice infected with wtVV showed se-
vere weight loss, whereas no weight loss was observed on
infection of mice even with several logs higher titer of
VV/OV-E3L and VVE3L. These results indicate that there
are subtle differences in the functioning of OV- and VV-
encoded E3L proteins, which were not apparent in cells-in-
culture but become evident on infection of the animal
model. The possibility of second site mutations in the virus
being the cause for the debilitation of VV/OV-E3L was
eliminated by restoring the virulence of this virus after
reinsertion of the full-length E3L gene.
Both wtVV and VV/OV-E3L replicated to high titers in
the nose of mice infected by the intranasal route. However
wtVV was detected in the lungs and brain of mice by 4 days
postinfection, while no VV/OV-E3L could be detected in
either organ. WR is a highly neurovirulent strain of VV and
replication in the central nervous system is likely the cause
of death in infected animals (Kaplan, 1989). The attenuated
phenotype of VV/OV-E3L could be due to inability of this
virus to replicate in the brain of infected animals. Alterna-
tively the block may have occurred due to the decreased
ability of this virus to spread to the various organs including
the brain. Since VV/OV-E3L is apparently non-neuroinva-
sive, we investigated the ability of this virus to produce
lethality if it was directly administered into the brain. On
intracranial injection VV/OV-E3L had LD50 greater than 1
 107 PFU—over 100,000-fold greater than that of wtVV
Fig. 7. Survival of mice following intranasal infection with recombinant
VV expressing chimeric E3Ls. Groups of 5 C57BL/6 mice 4–5 weeks of
age were infected with the indicated virus dose by the intranasal route and
the animals were observed for 2 weeks. All deaths were recorded and the
percentage survival of mice infected with each virus was determined.
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(LD50 100 PFU). The results of this study revealed that
VV/OV-E3L also has reduced replication efficiency in the
brain compared to wtVV. While wtVV replicated to nearly
109 PFU in the brain of infected mice, the amount of
VV/OV-E3L and VVE3L were 1.5–2.5 logs below the
amount seen in wt E3L-infected brains.
To identify the domain of VV- and OV-encoded E3L
protein that is responsible for the disparity in pathogenesis
of viruses expressing them, chimeric E3Ls were constructed
by interchanging the two domains of VV and OV E3L and
the resultant recombinant viruses were characterized in cell
culture and animals. Results of this study indicated that the
N-terminal domain of OV E3L could substitute for the
function of the N-terminal domain of VV E3L but the same
did not apply to the C-terminal domain of OV E3L. Since
the C-terminal domain of E3L is involved in binding
dsRNA, these results suggest that OV E3L may bind
dsRNA differently in comparison to VV E3L.
The N-terminal domain of both VV E3L and OV E3L
share considerable homology with the Z domain of a
cellular enzyme called adenosine deaminase (ADAR),
which edits the pre-mRNA that codes for ionotropic gluta-
mate gated cation channels in the brain (Keller et al., 1999;
Seeburg et al., 1998). Viral RNAs of measles, vesicular
stomatitis virus, respiratory syncytial virus, and parainflu-
enza virus 3 undergo hypermutations late during infection
and this is also believed to be due to the action of ADAR
(Cattaneo, 1994; Bass, 1997; Cattaneo and Billeter, 1992).
Herbert and Rich (1996) demonstrated that the Z domain
of ADAR binds to left-handed Z-DNA. Z-DNA has been
shown to be stabilized in vivo by negative supercoiling of
DNA, which occurs upstream of a moving RNA polymerase
(Liu and Wang, 1987). This has given rise to the suggestion
that the Z-DNA-binding domain of ADAR may target the
enzyme to actively transcribing genes, thereby ensuring that
editing can precede splicing of messages (Herbert and Rich,
1996). Based on crystal structure studies the interaction of
Z domain of ADAR with Z-DNA has been mapped mainly
to nine residues in the Z domain of human ADAR. Eight
of the nine amino acids required for the interaction of
ADAR with Z-DNA are conserved in both OV and VV
E3L. Although there is only 42% amino acid identity be-
tween the N-terminal domains of VV E3L and OV E3L, the
result of this investigation demonstrate that the N-terminal
domain of OV E3L can complement the deletion of the
corresponding domain of VV E3L in vitro as well as in vivo.
The recombinant VV expressing the chimeric E3L con-
struct where the C-terminal domain of VV E3L was re-
placed with the corresponding domain of OV E3L had an
IFN-resistant phenotype and broad host range in cells-in-
culture indistinguishable from that of wtVV and VV/OV-
E3L. However this virus was greatly debilitated in patho-
genicity (LD50  5  106 PFU following intranasal
infection) in the animal model. This indicates that the C-
terminal domain of OV E3L was unable to replace the
function of the homologous domain of VV E3L in the
animal model.
The C-terminal dsRNA binding domain of OV E3L (Fig.
1) shares 37% amino acid identity to the dsRNA binding
domain of VV E3L. This is comparatively less than the
50–90% homology shared between the E3L genes of other
poxviruses (VV, variola, cowpox, ectromelia, yabapox,
shope fibroma, myxoma) and other dsRNA-binding proteins
seen in prokaryotes and eucaryotes. The dsRNA-binding
domain of VV E3L shares approximately 40% identity to
the dsRNA-binding domain of ADAR and PKR. Analysis
of the molecular basis of interaction between dsRNA-bind-
ing proteins and dsRNA have revealed that residues homol-
ogous to F148, S166, K167, R168, and K171 of VV E3L
form a hydrophilic plane that interacts with the minor
groove of dsRNA (Bycroft et al., 1995; Kharrat et al., 1995;
Nanduri et al., 1998; Ryter and Schultz 1998; Ramos et al.,
2000). Mutational analysis demonstrates that these residues
of VV E3L protein are essential for binding to dsRNA (Ho
and Shuman, 1996a; Romano et al., 1998). These five amino
acids are conserved in the dsRNA-binding domain of OV
E3L. OV E3L does differs from VV E3L and from the
consensus dsRNA-binding motif at five positions (under-
lined in Fig. 1). Three notable differences are at VV E3L
Q127, P142, and A175. In the OV E3L, these residues
correspond to M119, E135, and C168, respectively. Two of
these residues, Q127 and A175, have been implicated in
stabilization of the hydrophobic core of the dsRNA-binding
domain of staufen and mutation of these residues resulted in
reduction in the ability of the protein to bind dsRNA
(Ramos et al., 2000). Studies done by Patel and co-workers
(1996) show that mutation of the alanine residue in PKR
that corresponds to A175 in VV E3L to aspartic acid totally
disrupted the ability of PKR to bind to dsRNA or oligomer-
ize. Thus, while it is unclear at this point how the alanine-
to-cysteine change seen at in this position in OV E3L affects
the dsRNA-binding affinity of this protein, it is likely that
the effect will be negative.
Apart from its use as smallpox vaccine, VV is also
widely employed as a vector for recombinant vaccines and
anticancer therapy. Due to the various safety issues associ-
ated with using of VV vectors (Fenner, 1989), the current
trend in vaccinology involves development of highly atten-
uated vectors (Moss, 1996; Pincus et al., 1995). Molecular
characterization of virulence genes of this virus could aid in
the development of better viral vectors for a wide range of
applications. Replacement of E3L, a virulence gene of VV,
with the OV E3L homologue resulted in a recombinant
virus that replicated as efficiently as wtVV in cells in culture
but was far more debilitated in pathogenicity in the animal
model. Apart from being a valuable tool to study the role of
E3L genes in the virulence of poxviruses, this recombinant
construct may prove to be a promising vector for use in
recombinant vaccines and anticancer therapy.
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Materials and methods
Sequence comparisons and vector construction
The protein sequence of VV E3L (WR strain) and OV
E3L homologue (OV20.0L gene of NZ2 strain of OV) was
compared using BLASTp program. The OV E3L homo-
logue was amplified by polymerase chain reaction (PCR,
92°C for 1 min, 50°C for 2 min, and 72°C for 3 min for 25
cycles) using gene-specific primers bearing BamHI and
HindIII restriction sites (5CTATGGATCCACAATGGCC-
TGCGAGTGC3 and 5ATCTAAGCTTAATTAGAAGC-
TGATGCCGC3). The PCR product was digested with
BamHI and HindIII and cloned into pMPE3Lgpt cleaved
with the same enzymes and this was used for recombining
that gene into the E3L locus of VV. The construction of
pMPE3Lgpt containing the VV E3L gene has been pre-
viously described (Kibler et al., 1997). The chimeric E3L
genes were constructed using pMPE3Lgpt with the VV
E3L gene cloned into it with BamHI and HindIII as the
parent plasmid. The N-terminal region of OV E3L was
amplified from pMPE3Lgpt containing OV E3L by PCR
using primers (5CTATGGATCCACAATGGCCTGCGA-
GTGC3 and 5TATTATGACGTCGGAGTTTTCGTCCT-
CC3) bearing BamHI and AatII using the same PCR
program described above. The PCR product was digested
with BamHI and AatII and cloned into pMPE3Lgpt
with E3L cleaved with the same enzymes. BamHI cleaves
just before the start of the VV E3L gene and AatII cleaves
at amino acid 83 of VV E3L. Using these restriction
enzymes, the N-terminal domain (1– 83) of VV E3L was
removed and replaced with the N-terminal domain (1–77)
of the OV E3L gene cloned in-frame with the C-terminal
domain of VV E3L (107–190) to generate a fusion
protein which was 184 amino acids long (VV N-ORF/C-
VV). Using a similar strategy, we generated the reverse
chimera (VV N-VV/C-ORF) expressing the N-terminal
domain of VV E3L (1– 83) fused to the C-terminal do-
main (77–183) of OV E3L gene. The C-terminal domain
of OV E3L was amplified using the following primers
(5ATGGCTGACGTCGAGCCCATGGAGACCGAGG3
and 5ATCTAAGCTTAATTAGAAGCTGATGCCGC3)
bearing AatII and HindIII sites and cloned into
pMPE3Lgpt containing VV E3L digested with the same
enzymes. The fusion protein (VV N-VV/C-ORF) was 189
amino acids long. Both fusion proteins were generated by
swapping domains at the less conserved middle region
which separates the N- and C-terminal domains of E3L
encoded proteins (Ho and Shuman, 1996b; McInnes et al.,
1998).
The recombinant VV expressing OV E3L (VV/ORF-
E3L), N-ORF/C-VV, N-VV/C-ORF, and the revertant for
VV/ORF-E3L were generated by in vivo recombination
using the pMPE3Lgpt recombination vector.
In vivo recombination
In vivo recombination (IVR) was performed using re-
combination vector pMPE3Lgpt and VVE3L was used
as the parent virus as described by Kibler et al. (1997). The
recombination vector pMPE3Lgpt has a selectable
marker, the Escherichia coli gpt gene, and regions homol-
ogous to that flanking the E3L gene in VV on either side of
the multiple cloning site to facilitate recombination into the
E3L locus of VV. The gpt gene allows the cells to utilize
hypoxanthine as a substrate for synthesizing guanine nucle-
otides in the presence of mycophenolic acid selection
(Falkner and Moss, 1988). Briefly subconfluent BHK-21
cells were infected with VVE3L at a multiplicity of infec-
tion (m.o.i.) of 5 and simultaneously transfected with 1 g
of plasmid containing the OV E3L using lipofectace
(Gibco-BRL). At 36 h postinfection, the cells were har-
vested and the resultant recombinant virus was plaque pu-
rified by X-gal staining of mycophenolic acid (MPA) resis-
tant plaques as described by Falkner and Moss (1988). The
MPA selection was withdrawn after three rounds and clear
plaques were selected in the absence of MPA in RK-13
cells. The sequences of the OV E3L genes in the recombi-
nant viruses were confirmed by DNA sequencing. A rever-
tant for the VV/ORF-E3L (VV/ORF-E3L rev) was con-
structed by inserting the VV E3L back into the recombinant
virus in place of OV E3L by recombining pMPE3Lgpt
containing the VV E3L gene into VV/ORF-E3L at the E3L
locus. Three rounds of plaque purification were performed
in the presence of MPA and two rounds of plaque purifica-
tion were performed in the absence of MPA to generate the
revertant virus.
Virus stocks and infections
Stocks of the recombinant viruses were generated by
amplification of a single plaque first in 35-mm dishes and
100-mm dishes of BHK-21 to generate high titer stocks.
Virus stocks were titrated in RK-13, aliquoted, and stored at
80°C. All virus dilutions were prepared in either MEM
containing 2% FBS or 1 mM Tris–HCl pH 8.8. Infection of
cell monolayers were performed after removing all the cell-
culture media, adding virus diluted to the appropriate vol-
ume, and incubating at 37°C in the presence of 5% CO2 for
1 h. Infected cells were rocked at intervals of 10 min.
Appropriate culture medium was overlaid on the monolayer
following infection.
Sequencing of viruses
Cell debris was removed from freeze-thawed virus
stocks by centrifugation at 1000 g for 10 min at 4°C. One
hundred microliters of virus stock of titer of 108 PFU/ml
was used for DNA extraction. Nucleic acid was obtained by
extracting with a mixture of 50 l phenol and 50 l chlo-
roform:isoamyl alcohol (24:1). The supernatant from this
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step was reextracted with chloroform:isoamyl alcohol and
precipitated with 2.5 volumes of ethanol (100%) and 1/10
volume of 3 M sodium acetate pH 5.2. The DNA was rinsed
twice with 70% ethanol, dried, and resuspended in 10 l
glass distilled water.
The OV E3L was amplified from this VV/ORF-E3L
DNA by PCR using primers that anneal to the flanking
regions of E3L (5CGAACCACCAGAGGATG3 and
5TAGTCGCGTTAATAGTACTAC3) under the same
conditions described above. The PCR product obtained
from the recombinant viruses was subjected to agarose gel
electrophoresis (0.8%, GTG grade, FMC) in TAE buffer
(0.04 M Tris acetate, 0.001 M EDTA) at 100 V for 45 min.
The DNA of interest was extracted from the band by first
freezing the DNA band overnight at 80°C and then thaw-
ing at 37°C for 30 min. The supernatant obtained from
freeze-thawing the gel slice containing the DNA band was
separated by centrifugation at 4°C for 15 min at 10,000 g
and subjected to ethanol precipitation. The DNA was resus-
pended in 12 l of glass distilled water. One microliter of
each of the primers (10 M stock) used for PCR was added
to 5.5 l of the DNA stock and sequenced by dideoxy
method.
Protein expression
The expression of the OV E3L by the recombinant virus
VV/ORF-E3L was confirmed by dsRNA binding. One
60-mm dish of RK-13 cells was infected with each virus (wt
VV, VVE3L, and VV/ORF-E3L) at an m.o.i. of 5. Cells
were incubated with [35S]methionine (50 Ci/ml) contain-
ing cell-culture media for 60 min from 3 h postinfection.
The cells were washed three times with phosphate-buffered
saline and harvested 4 h postinfection by centrifugation
(1000 g) at 4°C for 10 min. The cell pellet was resuspended
in 200 l NP-40 lysis buffer (20 mM HEPES pH 7.5, 120
mM KCl, 5 mM MgOAc, 1 mM DTT, 10% glycerol, and
0.5% NP-40) incubated on ice for 10 min and the cell nuclei
were removed by centrifugation at 10,000 g for 10 min at
4°C. The supernatant was transferred to a fresh tube and
stored on ice. The dsRNA agarose resin was washed three
times in ice-cold buffer A (20 mM HEPES pH 7.5, 10%
glycerol, 5 mM MgOAc, 100 mM KCl, 1 mM DTT, 1 mM
benzamidine) by centrifugation at 500 g at 4°C for 3 min.
Washed resin containing 50 g poly(rI) · poly(rC) was
added to each tube containing infected cell lysates and
incubated at 4°C for 1 h with constant rotation. For com-
petition assays, the extracts were incubated for 15 min at
4°C with a 10-fold excess of soluble nucleic acid prior to
incubation with the washed resin. Soluble nucleic acids
included poly(rI) · poly(rC), poly(rA), and salmon sperm
DNA. After incubation with the poly(rI) · poly(rC) resin, the
resin was washed three times in ice-cold buffer A. Follow-
ing the final wash, the pellet was suspended in 50 l 2
SDS sample buffer (100 mM Tris–HCl pH 6.8, 200 mM
DTT, 4% SDS, 0.2% bromophenol blue, and 20% glycerol).
The samples were boiled for 5 min and centrifuged at
13,000 g for 1 min. The supernatant was subjected to elec-
trophoresis at 200 V for 1 h using a 15% SDS–PAGE gel.
The gel was stained using Coomassie blue (1% Coomassie
blue R-250 in 40% methanol, 10% acetic acid), dried at
70°C for 2 h, and exposed to X-ray film for 24–48 h.
Interferon sensitivity assay
RK-13 cells were seeded at 50% confluency in six-well
plates. Four hours later the media overlaying the cells were
replaced with media containing different doses of rabbit
interferon- (480 IU/l, Lee Biomolecular) so that the final
concentration of IFN ranged from 0 to 1000 U/ml of cell-
culture media. Sixteen hours following IFN treatment, these
cells were infected with 100 PFU of each virus. wtVV was
used as a positive control since it is resistant to the effects
of IFN. VVE3L was used as a negative control. The
infected cells were incubated at 37°C and 5% CO2 for
36–48 h following which they were stained with 0.1%
crystal violet in 20% ethanol for 1 min at room temperature.
The plaques were counted in each well and plaque reduction
with increasing doses of IFN was computed as a percentage.
Host range
Six-well plates of RK-13 and HeLa cells at 90% conflu-
ency were infected with serial dilutions of VV/ORF-E3L,
wtVV (positive control), and VVE3L (negative control).
The infected cells were incubated at 37°C and 5% CO2 for
48 h following which they were stained with 0.1% crystal
violet in 20% ethanol.
Intranasal infection of mice
C57BL/6 mice, 4 weeks of age, were anesthetized using
a cocktail containing 7.5 mg/ml xylazine (Phoenix Pharma-
ceuticals, St. Joseph, MO), 2.5 mg/ml acepromazine mal-
eate, and 37.5 mg/ml ketamine (Fort Dodge Laboratories,
Fort Dodge, IA) at the rate of 1 l/g body weight of mice
administered by intramuscular injection. The mice were
then infected with serial dilutions of each virus in 1 mM
Tris–HCl pH 8.8 by intranasal route. The mice were
weighed on alternate days to monitor weight loss. All deaths
were recorded. The experiment was allowed to continue
until the mice appeared to be recovering from infection. The
surviving mice were euthanized 14 days postinfection using
an overdose of the inhalant anesthetic, halothane.
Tissue distribution
C57BL/6 mice, 4 weeks of age, were anesthetized and
infected with 106 PFU of each virus by intranasal route.
Animals were euthanized 5 days postinfection using an
overdose of halothane. The nasal turbinates, lungs, and
brains from these animals were harvested and quick-frozen
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using liquid nitrogen. The tissue samples were weighed and
made into 10% tissue suspension in MEM containing 5%
FBS and 100 g gentamycin using a Dounce homogenizer.
The samples were subjected to three rounds of freezing and
thawing and titrated in RK-13 cells. The limit of detection
of virus in each tissue was determined by adding known
amounts of wtVV to processed tissues from uninfected
mice, subjecting them to three rounds of freeze-thaws and
titration.
Intracranial infection of mice
C57BL/6 mice, 4 weeks of age, were anesthetized as
above and infected with serial dilutions of each virus by
intracranial injection using a 1 ml tuberculin syringe and a
27-gauge needle. The mice were weighed on alternate days
to monitor weight loss. Deaths were recorded. The experi-
ment was allowed to continue for 14 days following which
all the surviving mice were euthanized using an overdose of
the inhalant anesthetic, halothane. For assay of replication
in the brain, C57BL/6 mice, 4 weeks of age, were anesthe-
tized and injected with 106 PFU of each virus by intracranial
route. The brains from these animals were harvested 3 days
postinfection and quick frozen using liquid nitrogen. The
brain samples were weighed and made into 10% tissue
suspension in MEM containing 5% FBS and 100 g gen-
tamycin using a Dounce homogenizer. The samples were
subjected to three rounds of freezing and thawing and ti-
trated in RK-13 cells.
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